Praxair (NYSE: PX ) is expected to report Q4 earnings on Jan. 23. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Praxair's revenues will contract -0.6% and EPS will increase 1.5%.
The average estimate for revenue is $2.78 billion. On the bottom line, the average EPS estimate is $1.38.
Last quarter, Praxair logged revenue of $2.77 billion. GAAP reported sales were 4.2% lower than the prior-year quarter's $2.90 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.39. GAAP EPS of $1.43 for Q3 were 2.1% higher than the prior-year quarter's $1.40 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 42.5%, 60 basis points better than the prior-year quarter. Operating margin was 22.5%, 60 basis points better than the prior-year quarter. Net margin was 15.5%, 70 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $11.21 billion. The average EPS estimate is $5.57.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 670 members out of 695 rating the stock outperform, and 25 members rating it underperform. Among 162 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 160 give Praxair a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Praxair is outperform, with an average price target of $117.28.
The rich are different than you and me: They might not notice the moneymaking stories right under our noses. In our new report, "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice," we give you three Peter Lynch-inspired buy-what-you-know stocks for the 99%. Click here for instant access to this free report.
- Add Praxair to My Watchlist.